<DOC>
	<DOCNO>NCT02954276</DOCNO>
	<brief_summary>trial randomize , open label , crossover , single-administration bioavailability study compare pharmacokinetic parameter Omexa sumatriptan transmucosal sublingual tablet versus commercial Imitrex® sumatriptan oral tablet 14 healthy volunteer .</brief_summary>
	<brief_title>Comparative Bioavailability Study Omexa Sumatriptan vs. Imitrex® Healthy Volunteers</brief_title>
	<detailed_description>Volunteers randomly receive either commercial oral tablet 100 mg Imitrex® 75 mg Omexa sublingual tablet fast condition . One week follow first administration , volunteer receive alternative treatment . Blood sample collect visit drug administration 5 , 15 , 30 , 45 , 60 , 90 , 120 , 240 , 360 480 min drug administration , order characterize drug 's absorption pharmacokinetics , well evaluate Omexa formulation safety .</detailed_description>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>1 . Able provide write informed consent 2 . Man woman volunteer 1855 year age 3 . Healthy clinically relevant abnormality opinion investigator determine medical history , physical examination , urine analysis vital sign . 4 . Have BMI 1832 kg/m2 , inclusive , body weight less 50 kg 5 . Women childbearing potential agree use double contraceptive 14 day prior study , whole duration study 30 day completion study . 6 . The volunteer agree abstain alcohol intake 48 hour administration study agent inpatient portion study 7 . The volunteer agree consume food beverage contain , grapefruit grapefruit juice 72 hour prior study treatment last pharmacokinetic ( PK ) sample collect 8 . The volunteer agree frequent blood withdrawal 9 . The volunteer n't history fear needle injection , hemophobia ( fear blood ) 1 . Pregnant breastfeed woman ( woman child bear potential must use double contraceptive result negative pregnancy test record prior study drug administration ) 2 . Have history cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) 3 . Volunteers two risk factor ischemic heart disease 4 . History seizures 5 . History moderate severe hypertension mild uncontrolled hypertension systolic blood pressure 140 diastolic 90 screen visit 6 . Currently history disease dysfunction pulmonary , cardiovascular , endocrine , hematologic , neurological , immune , gastrointestinal , genitourinary , body system clinically significant opinion Investigator . 7 . History hypersensitivity allergy drug compound , include Sumatriptan , component sulphonamides ( Appendix 1 ) . 8 . History traumatic surgery within 12 week prior screen , preplanned surgery procedure would interfere conduct study . 9 . Have acute illness within 7 day prior study treatment major illness hospitalization within 1 month prior study treatment . 10 . History ( within 1 year ) alcohol drug abuse . 11 . Volunteers heavy smoker ( 10 cigarette day ) use nicotinereplacement therapy 12 . History abnormal value hematology , clinical chemistry , urine analysis six month prior treatment consider clinically significant Investigator . 13 . Positive test HIV antibodies screen 14 . Positive HBsAg test screening , volunteer bring certificate three dos Hepatitis B vaccination . 15 . Known history positive serology test hepatitis C virus antibody ( antiHCV ) 16 . Positive urine drug screen substance abuse include cocaine , cannabinoids , amphetamine , benzodiazepine , Subutex ( BUP ) , opiates , methadone screening . 17 . Have donate blood experience significant blood loss ( volume &gt; 500 mL ) within 3 month prior screen , plan donate within 2 month completion study . 18 . Use monoamine oxidase inhibitor ( MAOI ) within 28 day prior study treatment . 19 . Use prescription medications/products , except hormonal contraceptive , within 14 day prior study treatment . 20 . Use counter ( OTC ) , nonprescription preparation ( include mineral phytotherapeutic/herbal/plantderived preparation ) , within 14 day prior study treatment , exception ibuprofen , acetaminophen use recommended dos . 21 . Participation investigational study receipt investigational study treatment occur within 4 week prior dose , plan participate investigational study le 1 month completion study . 22 . Any condition opinion Investigator would complicate compromise study , wellbeing volunteer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>safety</keyword>
</DOC>